Lawyer finder

Patrick Duxbury

Partner
Patrick Duxbury

IP partner and head of the six-partner Life Sciences sector team delivering a unique mix of regulatory, anti-trust, IP, corporate and dispute resolution advice to many of the sector's key players.

Tel: +44 (0)121 214 1080
Email: patrick_duxbury@wragge.com

Services: Intellectual Property
Business sectors: Life Sciences

So, what do you do at Wragge & Co?

Typically my work includes advising on complex licence and collaboration deals, product acquisitions, joint ventures, fund raising, commercial agreements, M&A, protection and exploitation strategy and a variety of regulatory issues.

Best brains in ...

Life sciences transactional work and IP.

Highlight of your career so far?

Our first instruction for Japanese company Eisai - a global pharmaceutical company headquartered in Tokyo employing over 8,000 people in Asia, Europe and the US - on its $100 million acquisition of the European rights to pain suppressant Prialt ™. Under the agreement, Eisai obtained development, manufacturing and marketing rights for non-opioid severe chronic pain agent Prialt in Europe. Prialt is the synthetic equivalent of a peptide found in a marine snail. It suppresses pain by selectively blocking N-type calcium channels on nerves.

Most challenging job you've ever done?

That would have to be the work we did for Astex Therapeutics on its $520 million licensing and drug discovery agreement with Switzerland-based Novartis. The strategic alliance focused on the research, development and commercialisation of novel cell cycle control drugs for the treatment of cancer and other diseases. It was our second deal for Astex in six months and its largest-ever licensing deal.

What about outside the UK?

All our work is international, usually involving Japan, US and Europe.

What's your top tip for great client service?

Make your client feel like they are your only client. That means being well-organised and constantly available and if that means you have to work all night, well, you work all night!

When have you ever given a client a real competitive edge?

A client once asked my advice about the sums that they should require when out-licensing a drug. Because of my experience in the field, I advised them that the price they were asking was too low. They were surprised but reluctant to put the price up too high in case the other company walked away from the deal. I managed to persuade them to go in at the higher price and the other side accepted without question. For my clients it generated literally millions of dollars of income.

What's your single greatest contribution to Wragge & Co's corporate responsibility?

I'm a member of the firm's Eco Team which is working towards a greener Wragge & Co. I try and 'walk the talk' and encourage other partners to do the same by switching off monitors, encouraging re-cycling, catching the train and so on.

One of the best things about my job as a lawyer is that I get to work with a lot of companies with some really exciting technology which helps to save lives.

Alerts

13.02.09

Heart valve case by-passes experimental-use exemption

There is a dearth of UK case law on the application and scope of the experimental-use defence since the 1985 Monsanto v Stauffer decision.

29.01.09

The Pharmaceutical Sector Inquiry Preliminary Report: patent-related issues raised relevant to all patent intensive industries

Wragge & Co's first analysis of the EU Commission's preliminary report on the pharmaceutical sector looked at regulatory issues covered by the preliminary report. The IP team now moves on to consider the patent-related practices.

19.12.08

Pharmaceutical Sector Inquiry Preliminary Report

The European Commission has delivered its preliminary report on the findings from the Pharmaceutical Sector Inquiry launched in January 2008.

28.11.08

European Commission publishes preliminary findings of Pharmaceutical Inquiry - and opens up a hornets' nest

At a conference in Brussels today, the European Commission delivered its preliminary findings on the Pharmaceutical Sector Inquiry.

 

Press releases

10.01.12

Wragge & Co advises ProStrakan on cross-border agreement

Wragge & Co's Life Sciences team has advised ProStrakan Group plc on a cross-border licensing and distribution agreement with international pharmaceutical company Aptalis Pharma Inc.

16.05.11

Wragge & Co advises Heptares Therapeutics on multi-million deal double

Wragge & Co's Life Sciences team has completed two deals in a week for biotechnology company Heptares Therapeutics.

17.03.11

Wragge & Co secures cross-border agreement for Chroma Therapeutics

Wragge & Co's Life Sciences team has advised biotechnology company Chroma Therapeutics Ltd on a co-development and licensing agreement with biopharmaceutical company Cell Therapeutics Inc.

17.12.10

Wragge & Co advises Kennedy Research Institute on a new research centre to be created at the University of Oxford

Wragge & Co's Life Sciences team has advised the Mathilda and Terence Kennedy Institute of Rheumatology Trust (the KIR Trust) on a collaborative agreement with the University of Oxford to build a new rheumatology research centre on the Old Road campus at Oxford.

27.07.10

Wragge & Co advises on cross-border life sciences M&A deal

Wragge & Co's Corporate group has advised new client Bioline group on its US $23.3 million (£15.2 million) cross-border acquisition by NASDAQ-listed Meridian Bioscience Inc.

16.11.09

Wragge & Co advises Astex on £300 million drug discovery alliance

Wragge & Co LLP's Life Sciences team has advised long-standing client Astex Therapeutics Limited on a £300 million drug discovery alliance with healthcare giant GlaxoSmithKline (GSK).

24.06.09

Wragge & Co advises Chroma Therapeutics on billion dollar deal double

Wragge & Co LLP's cross-firm life sciences practice has advised biotechnology company Chroma Therapeutics Limited on two simultaneous transactions completed in one day.

01.06.09

Wragge & Co advises QinetiQ on disposal deal double

Wragge & Co LLP Corporate group has advised QinetiQ Group plc on an agreement to sell its underwater systems business to Atlas Elektronik UK for a cash consideration of £23.5 million.

01.04.09

Wragge & Co named European High-Tech Law Firm of the Year

Wragge & Co LLP Intellectual Property (IP) team has been named European High-Tech Law Firm of the Year by Managing Intellectual Property.

17.03.09

Wragge & Co advises Eisai on cross-border €95 million epilepsy deal

Wragge & Co LLP Life Sciences team has advised Eisai Europe Limited on a cross-border €95 million licence and co-promotion agreement with Bial-Portela & CA, S.A for the treatment for epilepsy.

17.06.08

Wragge & Co Life Sciences team advises Astex on $500 million drug discovery alliance

Wragge & Co LLP Life Sciences team has advised Astex Therapeutics Limited on a landmark $500 million drug discovery alliance with Janssen Pharmaceutica N.V.

28.04.08

Regulatory specialist joins Wragge & Co's Life Sciences team

Wragge & Co LLP has boosted its Life Sciences practice with a new regulatory specialist. Liz Fuller joins as director, life sciences regulatory (US qualified), bringing expertise in pharmaceutical and biotech regulatory affairs.

02.04.08

Wragge & Co's Life Sciences practice grows

Wragge & Co LLP has boosted its Life Sciences practice with the appointment of Dr Luke Kempton as a partner. With significant expertise in life sciences litigation, Luke will be a major force in driving forward the life sciences practice.

18.07.07

Wragge & Co advises AstraZeneca on collaboration with Silence Therapeutics

Wragge & Co LLP Life Sciences Team has advised AstraZeneca on its research and development collaboration with Silence Therapeutics to develop novel respiratory therapeutics.

05.07.07

Wragge & Co completes €41 million cross-border life sciences deal

Wragge & Co LLP's sector-focused Life Sciences Team has completed a €41 million cross-border life sciences deal for Japan's Eisai Co, Ltd.
 

Published articles

11.04.11

Wragge & Co advises on £91 million life sciences deal

Wragge & Co's corporate experts have advised Astex Therapeutics on its proposed £91 million cross-border acquisition by NASDAQ-listed SuperGen Inc.

14.01.09

Pharmaceutical patents need a new lease of life

Patrick Duxbury and Emma Tuck ask whether the increasing cost of drug development, and the declining numbers of drugs being approved, mean that IP protection for life science products should be reevaluated.

09.02.08

Patent pools in the pharmaceutical industry – sink or swim?

Patent pools as a tool for the collective management of intellectual property rights are not a new concept.

26.10.07

Patent misuse in the pharmaceutical industry: developments in US & EU

The pharmaceutical industry has been scrutinized closely by competition authorities and Courts in the US and Europe.

 

Search for lawyer